A blood test conducted in a prehospital setting may rapidly distinguish between ischemic and hemorrhagic stroke, potentially facilitating more rapid, targeted treatment. The test measures the levels ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

An ultra-sensitive blood test that reflects brain damage after acute ischemic stroke - and also predicts functional outcome. This is a discovery that is expected to be of great significance in the ...

Stroke seems to strike out of the blue, but it’s really cumulative effects that lead to stroke. Although it may seem like stroke is unpredictable and there is no way to pinpoint exactly when one might ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

Please provide your email address to receive an email when new articles are posted on . Recurrent strokes are common and many stroke patients do not receive adequate referrals. Patient and caregiver ...

Background Few studies have investigated patient-reported non-motor outcomes after stroke in young adults. We aimed to assess ...

Consent is an important consideration if introducing testing. A patient expert highlighted that people who have had a stroke often have severe cognitive impairment, may have difficulty with their ...